ClinicalTrials.gg
CompletedNCT03542305Updated Feb 21, 2021Results posted

Lorlatinib Renal Impairment Study

A Phase 1 interventional study of Lorlatinib in Renal Impairment, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
19th of 36
29 · median 30
Started
2018
with 2 others
Phase 1
23 of 37
2 open now
Registered
23rd of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 19th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2018, is one of 23 in phase 1, and was the 23rd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment.

Read the detailed description

This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment. Each subject will receive a single oral dose of lorlatinib administered in the fasted state. Subjects with mild, moderate, and severe renal impairment will be enrolled and normal healthy subjects will be enrolled as matched controls.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects of non-
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)
  • Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study
  • Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Demonstrate stable renal function

Exclusion criteria

Exclusion Criteria:

  • Renal allograft recipients
  • Any condition possibly affecting drug absorption (eg, gastrectomy)
  • A positive urine drug test
  • History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
  • Treatment with an drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
  • Screening supine triplicate 12 lead demonstrating a (QTc) interval >450 msec or a QRS interval >120 msec
  • Second-degree or third-degree AV block (unless paced) or baseline PR interval >180 msec at any time prior to dosing of study treatment.
  • Abnormalities in clinical laboratory tests at screening
  • Pregnant or breastfeeding female subjects
  • History of , , , HIT, sensitivity to heparin
  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Mild

    Mild renal impairment

    Drug: Lorlatinib

  • Experimental
    Moderate

    Moderate renal impairment

    Drug: Lorlatinib

  • Experimental
    Severe

    Severe renal impairment

    Drug: Lorlatinib

  • Other
    Normal

    Normal renal function

    Drug: Lorlatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib

    AUCinf was calculated by AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration; Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  2. Maximum Observed Plasma Concentration (Cmax) of Lorlatinib

    Cmax was observed directly from data.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event did not need to have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Number of participants with both all-causality and treatment-related TEAEs are presented below.

    Time frame: Baseline up to 28 days after last dose of study treatment (approximately 29 days)

  2. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities

    The hematology, chemistry and urinalysis tests were included in the laboratory examination. Hematology evaluation included hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte mean corpuscular volume, erythrocyte mean corpuscular hemoglobin concentration and erythrocyte mean corpuscular hemoglobin. Chemistry evaluation included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein, lipase and amylase. Urinalysis evaluation included decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy, ketones, nitrite, leukocyte esterase, urobilinogen, urine bilirubin and bacteria. The lab abnormalities were reported in accordance with the sponsor reporting standards.

    Time frame: Screening, Day -1, Day 2 and Day 6

  3. Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria

    Vital signs evaluations included supine diastolic blood pressure (DBP), and supine systolic blood pressure (SBP) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. Number of participants with vital signs data meeting the categorical summarization criteria is presented. The pre-specified criteria of vital signs data were categorized as follows: SBP (minimum) \<90 mmHg, maximum of decrease and increase from baseline for SBP \>=30 mmHg; DBP (minimum) \<50 mmHg, maximum of decrease and increase from baseline for DBP\>=20 mmHg.

    Time frame: Baseline up to 28 days after last dose of study treatment (approximately 29 days)

  4. Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Summarization Criteria

    ECG evaluation included: PR interval, time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval), and QT interval corrected for heart rate using Fridericia's formula (QTcF interval). The pre-specified criteria of ESG data were categorized as below.

    Time frame: Screening, Day -1, 0 hours (pre-dose), 1 hour, 2 hours, 4 hours, 24 hours and 120 hours postdose.

Other outcomes

  1. Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib

    AUClast was calculated by linear/Log trapezoidal method.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  2. Time for Cmax (Tmax) of Lorlatinib

    Tmax was observed directly from data as time of first occurrence.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  3. Terminal Elimination Plasma Half-life (t½) of Lorlatinib

    t1/2 was calculated by ln(2)/kel.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  4. Apparent Clearance After Oral Dose (CL/F) of Lorlatinib

    CL/F was calculated by Dose/AUCinf.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  5. Apparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib

    Vz/F was calculated by Dose/(AUCinf\*kel). kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

  6. Renal Clearance (CLR) of Lorlatinib

    CLR was calculated by Ae/AUClast. Ae was cumulative amount of drug recovered unchanged in urine, which was calculated by sum of (urine concentration × sample volume) for each collection interval from 0 to time 120 hours postdose. Sample volume = (urine weight in g/1.020), where 1.020 g/mL is the approximate specific gravity of urine.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose

07

Results

Posted Feb 21, 2021

Participant flow

The mild renal impairment participants were recruited first. After lorlatinib was tolerated in at least 3 mild impairment participants, moderate impairment participants were enrolled. After dosing of 3 moderate impairment participants for at least 1 week, the remaining moderate impairment participants and the severe impairment participants were enrolled. The enrollment of normal renal function participants began after all renal impairment participants completed the PK collection.

Participant flow — Overall Study
MilestoneNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Started8885
Completed8885
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib

AUCinf was calculated by AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration; Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib
ng*hr/mLNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib8329 ± 338683 ± 299890 ± 2711760 ± 37
Statistical analysis
  • Normal Function vs Mild Impairment · ANOVA · Ratio (%) of adjusted geometric means: 104.25 · 90% CI 79.73 to 136.31Normal renal function was the reference group. Mild renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
  • Normal Function vs Moderate Impairment · ANOVA · Ratio (%) of adjusted geometric means: 118.75 · 90% CI 91.43 to 154.24Normal renal function was the reference group. Moderate renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
  • Normal Function vs Severe Impairment · ANOVA · Ratio (%) of adjusted geometric means: 141.14 · 90% CI 97.82 to 203.66Normal renal function was the reference group. Severe renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Lorlatinib

Cmax was observed directly from data.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Lorlatinib
ng/mLNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Maximum Observed Plasma Concentration (Cmax) of Lorlatinib546.8 ± 48549.7 ± 52485.9 ± 24504.8 ± 50
Statistical analysis
  • Normal Function vs Mild Impairment · ANOVA · Ratio (%) of adjusted geometric means: 100.53 · 90% CI 66.48 to 152.02Normal renal function was the reference group. Mild renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
  • Normal Function vs Moderate Impairment · ANOVA · Slope: 88.87 · 90% CI 64.18 to 123.06Normal renal function was the reference group. Moderate renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
  • Normal Function vs Severe Impairment · ANOVA · Ratio (%) of adjusted geometric means: 92.32 · 90% CI 56.58 to 150.63Normal renal function was the reference group. Severe renal impairment was test group. The estimate was derived from ratio (%) of adjusted geometric means of Test and Reference.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event did not need to have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Number of participants with both all-causality and treatment-related TEAEs are presented below.

Time frame:
Baseline up to 28 days after last dose of study treatment (approximately 29 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
All-causality AEs5241
All-causality SAEs0000
Treatment-related AEs3211
Treatment-related SAEs0000
SecondaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities

The hematology, chemistry and urinalysis tests were included in the laboratory examination. Hematology evaluation included hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte mean corpuscular volume, erythrocyte mean corpuscular hemoglobin concentration and erythrocyte mean corpuscular hemoglobin. Chemistry evaluation included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein, lipase and amylase. Urinalysis evaluation included decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy, ketones, nitrite, leukocyte esterase, urobilinogen, urine bilirubin and bacteria. The lab abnormalities were reported in accordance with the sponsor reporting standards.

Time frame:
Screening, Day -1, Day 2 and Day 6
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities
ParticipantsNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities4285
SecondaryNumber of Participants With Vital Signs Data Meeting Categorical Summarization Criteria

Vital signs evaluations included supine diastolic blood pressure (DBP), and supine systolic blood pressure (SBP) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. Number of participants with vital signs data meeting the categorical summarization criteria is presented. The pre-specified criteria of vital signs data were categorized as follows: SBP (minimum) \<90 mmHg, maximum of decrease and increase from baseline for SBP \>=30 mmHg; DBP (minimum) \<50 mmHg, maximum of decrease and increase from baseline for DBP\>=20 mmHg.

Time frame:
Baseline up to 28 days after last dose of study treatment (approximately 29 days)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria
ParticipantsNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Supine SBP < 90 mmHg0100
Supine SBP ≥ 30 mmHg increase0021
Supine SBP ≥ 30 mmHg decrease1100
Supine DBP < 50 mmHg0100
Supine DBP ≥ 20 mmHg increase0011
Supine DBP ≥ 20 mmHg decrease0100
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Categorical Summarization Criteria

ECG evaluation included: PR interval, time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval), and QT interval corrected for heart rate using Fridericia's formula (QTcF interval). The pre-specified criteria of ESG data were categorized as below.

Time frame:
Screening, Day -1, 0 hours (pre-dose), 1 hour, 2 hours, 4 hours, 24 hours and 120 hours postdose.
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Summarization Criteria
ParticipantsNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
PR interval ≥ 200 to <220 msec0001
PR interval ≥ 200 to <240 msec0000
PR interval ≥ 240 to <260 msec0000
PR interval ≥ 260msec0000
QRS interval >120 msec0000
QT interval ≥ 500 msec0000
QTcF interval ≥ 450 to <480 msec0000
QTcF interval ≥ 480 msec0000
PR interval change from baseline ≥ 40 to <60 msec0010
PR interval change from baseline ≥ 60 to <80 msec0000
PR interval change from baseline ≥ 80 msec0000
PR interval percent change from baseline > 25%0010
QRS interval percent change from baseline ≥ 50%0000
QTcF interval change from baseline ≥ 30 to <60 msec0000
QTcF interval change from baseline ≥ 60 msec0000
Other pre-specifiedArea Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib

AUClast was calculated by linear/Log trapezoidal method.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib
ng*hr/mLNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib8015 ± 328307 ± 288867 ± 2410310 ± 36
Other pre-specifiedTime for Cmax (Tmax) of Lorlatinib

Tmax was observed directly from data as time of first occurrence.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Median · hours
Time for Cmax (Tmax) of Lorlatinib
hoursNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Time for Cmax (Tmax) of Lorlatinib1.50 (1.00 to 4.00)1.00 (1.00 to 1.50)1.25 (1.00 to 4.00)1.00 (1.00 to 1.50)
Other pre-specifiedTerminal Elimination Plasma Half-life (t½) of Lorlatinib

t1/2 was calculated by ln(2)/kel.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Mean · hours
Terminal Elimination Plasma Half-life (t½) of Lorlatinib
hoursNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Terminal Elimination Plasma Half-life (t½) of Lorlatinib25.64 ± 4.750028.08 ± 3.515639.40 ± 7.101941.66 ± 7.6081
Other pre-specifiedApparent Clearance After Oral Dose (CL/F) of Lorlatinib

CL/F was calculated by Dose/AUCinf.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · L/hr
Apparent Clearance After Oral Dose (CL/F) of Lorlatinib
L/hrNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Apparent Clearance After Oral Dose (CL/F) of Lorlatinib12.02 ± 3311.51 ± 2910.11 ± 278.51 ± 37
Other pre-specifiedApparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib

Vz/F was calculated by Dose/(AUCinf\*kel). kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · L
Apparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib
LNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Apparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib436.9 ± 24462.9 ± 27566.2 ± 21503.8 ± 36
Other pre-specifiedRenal Clearance (CLR) of Lorlatinib

CLR was calculated by Ae/AUClast. Ae was cumulative amount of drug recovered unchanged in urine, which was calculated by sum of (urine concentration × sample volume) for each collection interval from 0 to time 120 hours postdose. Sample volume = (urine weight in g/1.020), where 1.020 g/mL is the approximate specific gravity of urine.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Reported as:
Geometric mean · L/hr
Renal Clearance (CLR) of Lorlatinib
L/hrNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Renal Clearance (CLR) of Lorlatinib0.1095 ± 420.1382 ± 500.08199 ± 550.06872 ± 45

Adverse events

Collected over Baseline up to 28 days after last dose of study treatment (approximately 29 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Function0/8 (0%)0/8 (0%)5/8 (62.5%)
Mild Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Moderate Impairment0/8 (0%)0/8 (0%)4/8 (50%)
Severe Impairment0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventNormal FunctionMild ImpairmentModerate ImpairmentSevere Impairment
Blood pressure increasedInvestigations0/81/80/81/5
HyperglycaemiaMetabolism and nutrition disorders0/80/80/81/5
DyspnoeaRespiratory, thoracic and mediastinal disorders0/80/80/81/5
DiarrhoeaGastrointestinal disorders1/80/81/80/5
MyalgiaMusculoskeletal and connective tissue disorders0/81/80/80/5
DizzinessNervous system disorders1/80/81/80/5
HeadacheNervous system disorders1/80/81/80/5
Vessel puncture site painGeneral disorders0/81/80/80/5
Upper respiratory tract infectionInfections and infestations1/80/81/80/5
Skin abrasionInjury, poisoning and procedural complications0/80/81/80/5

Baseline characteristics

Baseline analysis population included all participants who were randomized.

Age, Continuous
Age, Continuous(Years)Normal FunctionMild ImpairmentModerate ImpairmentSevere ImpairmentTotal
Mean56.6 ± 3.6659.0 ± 7.2763.1 ± 4.8860.4 ± 11.0859.7 ± 6.81
Sex: Female, Male
Sex: Female, Male(Participants)Normal FunctionMild ImpairmentModerate ImpairmentSevere ImpairmentTotal
Female335112
Male553417
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Normal FunctionMild ImpairmentModerate ImpairmentSevere ImpairmentTotal
white578323
Black or African American30025
Asian01001
08

Study locations

2 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Prism Clinical Research, LLC
    Saint Paul, Minnesota 55114, United States
09

References and documents

Publications

  • Lin S, Gong J, Canas GC, Winkle P, Pelletier K, LaBadie RR, Ginman K, Pithavala YK. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):235-245. doi: 10.1007/s13318-021-00747-4. Epub 2022 Jan 11. Erratum In: Eur J Drug Metab Pharmacokinet. 2022 May;47(3):441. doi: 10.1007/s13318-022-00759-8. PubMed 35018553 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2020, 17 months.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2018
First posted
May 31, 2018
StartActual
Aug 23, 2018
Primary completionActual
Feb 20, 2020
CompletionActual
Feb 20, 2020
Results first posted
Feb 21, 2021
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03542305
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 31, 2018
Start date
Aug 23, 2018
Primary completion
Feb 20, 2020
Completion
Feb 20, 2020
Results posted
Feb 21, 2021
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion